Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the obesity drug developer for $4.9 billion. Novo Nordisk, a finalist in that pursuit, is positioning itself as a deal spoiler with a new unsolicited offer that shells out much more upfront cash.
The post Novo Nordisk Swoops In With $6.5B Bid to Top Pfizer’s M&A Deal With Obesity Biotech Metsera appeared first on MedCity News.
